Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Puma Biotechnology (NQ: PBYI ) 2.950 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Puma Biotechnology < Previous 1 2 3 4 Next > Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results October 24, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 03, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) August 06, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology Reports Second Quarter Financial Results August 01, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results July 18, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) July 02, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) June 07, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer June 03, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041) June 02, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology to Join Russell 3000 Index May 28, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting May 23, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology Reports First Quarter Financial Results May 02, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results April 18, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) April 03, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer March 20, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results February 29, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) February 27, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference February 22, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results February 15, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer February 13, 2024 From Puma Biotechnology, Inc. Via Business Wire 3 small-cap biotechs with potential breakthroughs in 2024 February 06, 2024 These small-cap biotech stocks feature large addressable markets combined with positive analyst sentiment and potential breakthroughs in 2024. Via MarketBeat Topics Bankruptcy Exposures Financial Legal Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference January 11, 2024 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer December 11, 2023 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) November 06, 2023 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology Reports Third Quarter 2023 Financial Results November 02, 2023 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results October 19, 2023 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting October 14, 2023 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) October 04, 2023 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer September 21, 2023 From Puma Biotechnology, Inc. Via Business Wire Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 31, 2023 From Puma Biotechnology, Inc. Via Business Wire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
